First In Human By Vial Vial

Explore the untapped potential of RNA amplifying therapeutics with the CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting the course of gene expression and a guide to the regulatory RNAs that can turn up the volume on genes gone silent due to disease. It's a pion...

Embark on a journey through the neurons and synapses of brain science with William Korinek, the CEO of Astrocyte Pharmaceuticals. In a conversation that fuses the molecular intricacies of neuroprotection with the humanistic pursuit of medical advancement, Bill reveals his unique path from molecular biologist to biotech innovator. Together, we unravel the complexities of securing funding, the importance of strategic networking, and the scarcity of research dollars for conditions impacting mill...

In this episode, Rachel Haines from Rinri Therapeutics joins us to discuss the possibilities of cell therapy for hearing loss. Our conversation with Rachel goes beyond just scientific innovation; we also explore the potential impact of Rinri's upcoming human trials, which are based on Professor Marcelo Rivolta's groundbreaking work. By delving into the challenges and excitement of pioneering clinical trials in uncharted territory, we envision a future where natural hearing restoration could b...

Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte's focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regulatory considerations, and Lixte's ambitious long-term goals in expanding their impact on cancer care. Tune in to explore the cutting-edge science an...

Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals.First ...

Imagine unlocking the secrets to revitalizing the brain's energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug's conception to the exciting clinical trial results that highlight its capacity to enhance neurological functions and offer new hope to individuals grappling with ALS and...